Web Results

Anti-TNF therapy is associated with an increased risk of serious ...


Jul 31, 2010 ... The unadjusted rates of SI were higher in the anti-TNF cohort (42 vs 32 events per 1000 patient-years of follow-up). Univariate ..... Zink A, Strangfeld A, Schneider M, et al. .... Abraham E, Wunderink R, Silverman H, et al.

A prospective study comparing infection risk and disease activity in ...


Sep 18, 2014 ... The total infection rate ratio for TNF versus non-TNF group subjects ... retrospective cohort studies by Beukelman et al. demonstrated that JIA ..... Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. ... Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al.

Updated consensus statement on the use of rituximab in patients ...


Mar 6, 2011 ... Strangfeld A, Eveslage M, Kekow J, et al. ... Silverman GJ, Schwartzman S, Townsend M, et al. .... Chatzidionysiou S, Carli C, Van Vollenhoven R. Rituximab versus anti-TNF in patients who have previously failed one or more ...

Silverman et al., 2009 - Google Scholar

scholar.google.com/scholar_lookup?title=Coral reefs may start dissolving when atmospheric CO2 doubles&author=Silverman&publication_year=2009

DSQ Spring 2013 - American College of Rheumatology

www.rheumatology.org/Portals/0/Files/DSQ Spring 2013.pdf

Mar 5, 2013 ... Daien CI, Fesler P, du Cailar G, Daien V, Mura T, Dupuy AM, et al. ... III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al.

Positivity for anti-cyclic citrullinated peptide is associated with a ...


May 21, 2012 ... Gottenberg JE, Ravaud P, Cantagrel A, et al. Ann Rheum Dis ... (anti-CCP)- positivity (75.9% vs 62.2%, p= 0.001) were ..... Strangfeld A, Hierse F, Rau R, et al . Risk of ... Silverman GJ, Schwartzman S, Townsend M, et al.

Leflunomide in the treatment of rheumatoid arthritis - UpToDate


Apr 21, 2015 ... Silverman E, Mouy R, Spiegel L, et al. Leflunomide ... Dziedziejko V, Kurzawski M , Safranow K, et al. .... Strangfeld A, Hierse F, Kekow J, et al.

Download - eScholarship@UMMS - University of Massachusetts ...


Jul 1, 2015 ... Silverman featuring research articles on clinical subjects from scientists working is a monthly ... moderate/high disease activity at baseline exposed to ≥ 2 versus 1 prior anti-TNF was 0.40 (95% CI ... Harrold, et al: Real-world effectiveness of RTX ...... Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F,.

Staphylococcus aureus Protein A Binds to Osteoblasts and Triggers ...


Apr 15, 2011 ... (B+C) To measure Annexin V binding pelleted osteoblasts were ..... O'Seaghdha M, van Schooten CJ, Kerrigan SW, Emsley J, Silverman GJ, et al. .... Haslinger- Loffler B, Kahl BC, Grundmeier M, Strangfeld K, Wagner B, et al.

Longterm Safety, Efficacy, and Inhibition of Structural Damage ...


Jun 1, 2014 ... an international journal edited by Earl D. Silverman ..... as outlined by Buch, et al, should be taken into consideration when interpreting ... Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, .... Listing J,; Strangfeld A,; Kary S,; Rau R,; von Hinueber U,; Stoyanova-Scholz M,; et al.

More Info

Evidence-based psychosocial treatments for children and ... - NCBI


Silverman WK(1), Ortiz CD, Viswesvaran C, Burns BJ, Kolko DJ, Putnam FW, ... each of these 21 studies also are classified using criteria from Chambless et al.

Staphylococcus aureus Virulence Factors Synthesis is Controlled by ...


v. Table of Contents. Abstract… ..... or depleting innate-like B cells (Goodyear and Silverman 2004; Bekeredjian-Ding,. Inamura et al. 2007). Protein A can ... dependent and caspase-independent apoptosis (Haslinger, Strangfeld et al. 2003).

John Strangfeld, Prudential CEO - Hartford Courant


Prudential Financial Inc. Chairman and CEO John R. Strangfeld was compensated $24.76 million last year, up 36 percent from the $18.16 million he received in ...